John M Nuss

This inventor holds 55 USPTO granted patents and 31 published patent applications, plus 4 CIPO patents and 23 EPO patents, primarily in Kinase Modulators. Top assignees: Exelixis, Inc., Chiron Corporation, Escalier Biosciences B.v.. Active years: 1999-2026.

USPTO Granted Patents = 55 (Patent Applications = 31)

% Patents Active = 47.3

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 23 (Patent Applications = 30)

Average Co-Inventor Count = 5.6

ph-index = 17

Forward Citations = 839(Granted Patents)

Forward Citations (Not Self Cited) = 775(Dec 10, 2025)

Location History:

San Diego, CA (US) (2020)
Danville, CA (US) (1999 - 2021)
Carlsbad, CA (US) (2021)
Encinitas, CA (US) (2021 - 2023)

Company Filing History:

Escalier Biosciences B.v.

patents

4. 3 out of 10

Symphony Evolution, Inc.

patents

5. 3 out of 3

Zomagen Biosciences Ltd

patents

6. 2 out of 245

Novartis Vaccines & Diagnostics, Gmbh

Ventyx Biosciences, Inc.

patents

9. 2 out of 2

Vimalan Biosciences, Inc.

patents

10. 1 out of 460

Daiichi Sankyo Company, Limited

where one patent can have more than one assignee

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Kinase Modulators

JAK Inhibitors

NLRP3 Modulators

c-Met Modulators

TYK2 Pseudokinase

ROR-Gamma Modulators

Phosphatidylinositol 3-Kinase

Anaplastic Lymphoma Kinase

Small Molecule Inhibitors

P70S6 Kinase

Heterocyclic Compounds

Immunological Treatment

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12612401 - Crystalline forms of an S1P receptor modulator (2026-04-28),

2. 12466800 - N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) (2025-11-11),

3. 12351564 - NLRP3 modulators (2025-07-08),

4. 11780842 - TYK2 pseudokinase ligands (2023-10-10),

5. 11753411 - Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands (2023-09-12),

6. 11603375 - NLRP3 modulators (2023-03-14),

7. 11459333 - Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors (2022-10-04),

8. 11242350 - Spirocyclic ROR-gamma modulators (2022-02-08),

9. 11230555 - Bicyclic RORγ modulators (2022-01-25),

10. 11136329 - JAK inhibitors (2021-10-05),

11. 11124482 - C-met modulators and methods of use (2021-09-21),

12. 10905687 - Substituted piperazines as ROR-gamma modulators (2021-02-02),

13. 10683291 - Heterocyclic compounds for the treatment of disease (2020-06-16),

14. 9174947 - c-Met modulators and methods of use (2015-11-03),

15. 8889664 - Phosphatidylinositol 3-kinase inhibitors and methods of their use (2014-11-18),

Title: The Inventor John M Nuss: Pioneering Innovations in Danville, CA

Introduction: John M Nuss is a distinguished inventor based in Danville, CA, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: John M Nuss holds several patents in the areas of technology, healthcare, and sustainability, showcasing his versatility and forward-thinking approach to problem-solving.

Career Highlights: With a career spanning over two decades, John M Nuss has established himself as a visionary inventor, with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of conventional thinking.

Collaborations: Throughout his career, John M Nuss has collaborated with leading research institutions, universities, and companies to bring his inventions to life, fostering a culture of innovation and excellence in the industry.

Conclusion: John M Nuss's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazing inventor, shaping the future of technology and beyond.